CN Patent

CN119055604A — 含有对乙酰氨基酚和布洛芬的药物组合物

Assigned to AFT Pharmaceuticals Ltd · Expires 2024-12-03 · 1y expired

What this patent protects

本发明涉及一种固体口服剂型，例如为一种片剂，包含325mg对乙酰氨基酚和97.5mg布洛芬或500mg对乙酰氨基酚和150mg布洛芬，其中所述布洛芬的[D50]为2‑8μm、[D10]为1‑3μm且[D90]为4‑16μm。

USPTO Abstract

本发明涉及一种固体口服剂型，例如为一种片剂，包含325mg对乙酰氨基酚和97.5mg布洛芬或500mg对乙酰氨基酚和150mg布洛芬，其中所述布洛芬的[D50]为2‑8μm、[D10]为1‑3μm且[D90]为4‑16μm。

Drugs covered by this patent

Patent Metadata

Patent number
CN119055604A
Jurisdiction
CN
Classification
—
Expires
2024-12-03
Drug substance claim
No
Drug product claim
No
Assignee
AFT Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.